ALK(SZ:002940) Xin Lang Cai Jing·2025-11-05 03:37Group 1 - The core point of the news is that Anglikon experienced a decline of 5.14% in its stock price, reaching 38.73 yuan per share, with a trading volume of 711 million yuan and a turnover rate of 9.47%, resulting in a total market capitalization of 7.813 billion yuan [1] - Anglikon Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and was established on December 30, 2001, with its listing date on October 23, 2018. The company specializes in the research, production, and sales of chemical raw materials and formulations [1] - The main business revenue composition of Anglikon includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, others at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - From the perspective of major fund holdings, Invesco Great Wall Fund has a significant position in Anglikon, with its Invesco Great Wall Medical Industry Stock A (022081) increasing its holdings by 72,000 shares in the third quarter, totaling 120,000 shares, which accounts for 5.98% of the fund's net value, ranking as the ninth largest holding [2] - The Invesco Great Wall Medical Industry Stock A (022081) was established on January 24, 2025, with a latest scale of 31.4463 million. Since its inception, it has achieved a return of 36.99% [2] - The fund manager, Qiao Haiying, has a tenure of 11 years and 58 days, with the total asset scale of the fund being 1.182 billion yuan. The best fund return during her tenure is 147.43%, while the worst return is -12.35% [2]